According to TipRanks, Maenhaut is a 4-star analyst with an average return of 4.6% and a 46.77% success rate.

Currently, the analyst consensus on Ion Beam Applications SA IBA is a Moderate Sell with an average price target of €11.75.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

Ion Beam Applications SA IBA (0GZK) Company Description:

Ion Beam Applications SA develops and manufactures medical devices and software solutions. The firm operates in two segments: proton therapy and other accelerators and dosimetry. Proton therapy and other accelerators business contribute to the majority of sales. It offers solutions for precision cancer treatment through the use of proton beams, as well as cyclotrons used for the production of radioisotopes and industrial accelerators for sterilization and ionization. The dosimetry business sells measurement and quality assurance instruments for radiotherapy and medical imaging. The firm operates in three geographical areas: Belgium, the United States, and Rest of World, with REst-of-World sales generating the largest proportion of revenue.